A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Investigator: Tejal Patel, MD

Study Coordinator: Minh Truong

Status: Enrolling

ClinicalTrials.gov Number: NCT02954874

Phone: 346.238.6403

Protocol Number: Pro00018449


This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
More to Explore
Live Chat Available